Contact us

877-469-1TRM
424-208-8866

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC)

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer CDX-011 II Open and Accruing